Literature DB >> 8003743

Pathology of chronic inflammatory bowel disease in children.

P Domizio1.   

Abstract

The term chronic inflammatory bowel disease is usually applied to the idiopathic varieties ulcerative colitis and Crohn's disease but actually encompasses a wide range of colonic inflammatory conditions, which in children includes indeterminate colitis, microscopic colitis, allergic colitis and Behçet's enterocolitis. The pathologist's opinion is considered the final arbiter in the diagnosis of inflammatory bowel disease but classification may be hampered by the considerable histological overlap between the various types of colitis. Accurate diagnosis, particularly in biopsy specimens, thus depends on clinical and radiological input as well as on appropriately selected and adequately prepared material. This chapter discusses in detail the morphological appearances of ulcerative colitis and Crohn's disease with particular emphasis on diagnosis by mucosal biopsy and differential diagnosis in the paediatric age group. The recent demonstration of ulceration-associated cell lineage and trefoil peptide expression in inflammatory bowel disease is also discussed.

Entities:  

Mesh:

Year:  1994        PMID: 8003743     DOI: 10.1016/s0950-3528(06)80018-7

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


  3 in total

Review 1.  Chronic inflammatory bowel disease in children: a complex problem in management.

Authors:  J A Walker-Smith
Journal:  Postgrad Med J       Date:  2000-08       Impact factor: 2.401

2.  Clear cell colitis: a form of microscopic colitis in children.

Authors:  Jan Józefczuk; Bogdan Marian Wozniewicz
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

3.  VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis.

Authors:  Cong Dai; Chang-Qing Zheng; Fan-Ji Meng; Zheng Zhou; Li-Xuan Sang; Min Jiang
Journal:  Mol Cell Biochem       Date:  2012-10-23       Impact factor: 3.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.